Neuroendocrine tumors (NET) trials

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors is being studied. Conditions: Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum +30 • Eligibility: Inclusion Criteria: * Age ≥ 36 months and \< 22 years * Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive…. Goal: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) is being studied. Conditions: Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion Criteria: * Patients with relapsed/refractory CLL who meet iwCLL criteria for requiring treatment. * Patients with measurable disease as defined by at least one of: circulating lymphocytosis…. Goal: This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody) Phase/Status/Sponsor: Unknown phase; RECRUITING; Jennifer R. Brown, MD, PhD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic disease in bone documented on bone scan, or in soft tissue…. Goal: This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FTT PET/CT in Pancreatic Neuroendocrine Tumors is being studied. Conditions: Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors • Eligibility: Inclusion Criteria: 1. Patients must be ≥ 18 years of age. 2. Clinical diagnosis of a metastatic or unresectable grade 1, grade 2 or grade 3 (G1/G2/G3) pancreatic…. Goal: A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). Phase/Status/Sponsor: Unknown phase; RECRUITING; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study With [225Ac]Ac-FL-020 in mCRPC Participants is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed metastatic CRPC. 2. Age ≥ 18 years. 3. Signed informed consent, and able and willing to comply with protocol requirements prior…. Goal: The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Full-Life Technologies GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients is being studied. Conditions: Follicular Lymphoma • Eligibility: Inclusion Criteria: 1. Able to provide written informed consent form approved by the National Ethics Committee (NEC) prior to the initiation of any screening or study-specific procedures and…. Goal: This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione Italiana Linfomi - ETS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests Sapu003 in adults with advanced mTOR-sensitive solid tumors, in two groups: Cohort A will receive Sapu003 with exemestane for HR+/HER2-negative breast cancer, and Cohort B will receive Sapu003 alone for RCC, NETs, TSC-associated tumors, or HCC. - This is a phase 1b, open-label, dose-escalation study to find the maximum tolerated dose and to assess safety, pharmacokinetics, and any early antitumor activity. - Eligibility includes adults 18 years or older with the specified cancers, ECOG 0–2, and adequate organ function; key exclusions include active brain metastases, uncontrolled infections or other serious conditions, HIV/HBV/HCV infection, recent major surgery, and pregnancy or breastfeeding. - Sapu003 will be given as weekly IV infusions at 5, 7.5, or 10 mg/m2 in 28-day cycles.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests precision-based immunotherapy approaches for primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and aims to build a biospecimen repository to study the biology of the cancer and how patients respond to treatment. - It will enroll adults 18 and older with liver cancer who are receiving or planning to receive immunotherapy, and will collect medical records, imaging, tumor tissue, and samples such as blood, urine, and stool over time. - Researchers will perform a wide range of analyses (genomics, epigenetics, metabolomics, microbiome, and immune monitoring) to identify factors that predict response or resistance to immunotherapy and to understand disease progression. - HIV infection is an exclusion criterion, and the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Key Longitudinal Associations With Risk and Glioblastoma Outcomes is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * At least 18 years old * Pathologically-confirmed diagnosis of glioblastoma multiforme (GBM) or grade 4 brain tumor * Participant is accessible for follow-up (has a…. Goal: The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer. The main questions it aims to answer are: * How do genetic and immune system factors impact survival and quality of life in GBM patients? Phase/Status/Sponsor: Unknown phase; RECRUITING; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection is being studied. Conditions: Pancreatic Cyst • Eligibility: Inclusion Criteria: * Patients ≥ 18 years old. Patients under 18 are excluded due to their potential inability to understand and consent independently to the methods required for…. Goal: To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Blood Markers of Early Pancreas Cancer is being studied. Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst +3 • Eligibility: Inclusion Criteria: * Age ≥19 * Able to provide written, informed consent * Able to attend an in-person study visit in Omaha, NE twice a year to collect…. Goal: Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Nebraska.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy is being studied. Conditions: Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma, Distal Cholangiocarcinoma +2 • Eligibility: Inclusion Criteria: * Age ≥18 years. * Histologically confirmed or clinically suspected lesions of: Pancreatic head adenocarcinoma, Ampullary carcinoma, Distal cholangiocarcinoma, Duodenal adenocarcinoma, Pancreatic neuroendocrine tumors, or Intraductal…. Goal: This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD). The study aims to determine the morbimortality of the laparoscopic approach compared to the gold standard open approach in adult patients with pancreatic or periampullary lesions. Phase/Status/Sponsor: Unknown phase; RECRUITING; Minia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI. is being studied. Conditions: Locally Advanced or Metastatic Breast Cancers • Eligibility: Inclusion Criteria: 1. Women (or men) aged ≥ 18 years on the day of signing the informed consent with histologically proven breast cancer. 2. Metastatic or locally advanced…. Goal: This is a multicenter, prospective, non-randomized, open-label, pharmacokinetic study, aiming to compare the plasma exposure of the payload (free-DXd) in patients treated by T-DXd for locally advanced or metastatic breast cancer according to their BMI. The primary objective is to compare plasma exposition of the payload (free-DXd) between overweight or obese (BMI\>25) and normal weight (BMI≤25) breast cancer patients during the first 3 cycles of Trastuzumab-Deruxtecan (T-DXd). Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Claudius Regaud.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a retrospective, multicenter study that looks at adults with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) to see how tumor features and patient factors affect response to treatments like somatostatin analogs, sunitinib or everolimus, and capecitabine-temozolomide. The main goal is to learn whether these factors influence time to progression (progression-free survival) under treatment. In a San Raffaele Hospital subset, researchers will also explore transcriptome signatures as potential biomarkers of different treatment responses. Eligible participants are adults with well-differentiated, localized (not surgically removable) or advanced GEP-NENs who have been treated with the listed therapies for at least 6 months; key exclusions include being under 18, pregnancy or breastfeeding, poorly differentiated NEC or MiNEN, unknown primary tumors, prior radioligand therapy, and concurrent loco-regional treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia is being studied. Conditions: ALL, Childhood, Pediatric Cancer, Toxicity, Drug +5 • Eligibility: Inclusion Criteria: * Age \> 1 year old and ≤18 years old at enrolment * Previously untreated * ALL diagnosis confirmed by morphology and flow-cytometry * Indian origins…. Goal: A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Geneva, Switzerland.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether markers of neutrophil extracellular traps (NETosis) can predict future thrombosis in people with certain myeloproliferative neoplasms (MPNs). It focuses on adults with JAK2V617F-positive PV, essential thrombocythemia, or pre-myelofibrosis who are at high risk for blood clots. Researchers will measure NETosis markers (calprotectin and H3Cit) at baseline and after 12 months, then follow participants for 24 months to see if these markers relate to thrombotic events and help guide prevention. Eligibility includes having the relevant MPN and high thrombotic risk, being enrolled in the AVAJAK trial and a biobank, and not having severe kidney or liver failure, being under guardianship, or using heparin at entry.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort is being studied. Conditions: Prostate Cancer, Magnetic Resonance Imaging, Population at Risk • Eligibility: Inclusion Criteria: 1. PSA between 1.0 and 2.5 ng/dL 2. High risk for prostate cancer, i.e. Black or they have a first degree relative with history of prostate…. Goal: To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols. Phase/Status/Sponsor: Unknown phase; RECRUITING; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma is being studied. Conditions: Advanced (Unresectable or Metastatic) Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent (or adulthood where the legalage of majority in the country is established \>18 years).…. Goal: This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; mAbxience Research S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia is being studied. Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia • Eligibility: Inclusion Criteria: 1. Subject must have confirmation of non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine). 2. Subject must have relapsed…. Goal: This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether objectively measured physical activity, collected with wearables, is linked to ECOG performance status and overall survival in adults with advanced cancer. - It is for adults with various advanced cancers who live in the Houston area and can participate in English. - The trial also looks at whether wireless data collection and transfer into the CYCORE system is feasible and acceptable in real-world cancer care. - Key exclusions include recent major surgery, certain cognitive or unstable heart/lung conditions, lack of home internet/WiFi, pregnancy, pacemakers, or current enrollment in conflicting protocols.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic trial tests adding venetoclax to three standard myeloma regimens—Rd (lenalidomide+dexamethasone), Dd (daratumumab+dexamethasone), and DRd (daratumumab+lenalidomide+dexamethasone)—in adults with multiple myeloma, focusing on the t(11;14) abnormality. It uses a dose-escalation design to find the recommended phase II dose of venetoclax and to assess safety, side effects, and how well the treatment works. The study has two groups: relapsed myeloma (Group 1) and newly diagnosed myeloma (Group 2), with assignment to the different arms accordingly. Eligibility requires measurable disease and adequate organ function; key exclusions include recent other cancers (with some exceptions), HIV, certain drug interactions (CYP3A inhibitors/inducers), major GI issues, recent major surgery, and pregnancy risk with lenalidomide-containing therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes is being studied. Conditions: Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms +76 • Eligibility: Inclusion Criteria: * Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study…. Goal: Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests genetic analysis to identify genes involved in pheochromocytoma and paraganglioma and to learn how different mutations relate to the disease. It is for people with pheochromocytoma or paraganglioma, their family members, or those with related conditions. The researchers aim to discover new susceptibility genes and to understand genotype-phenotype relationships to guide diagnosis, surveillance, and genetic screening of relatives. The study is currently recruiting, and people with an unconfirmed diagnosis are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: * CLL or SLL diagnosis * Patients must have been diagnosed with CLL (\> 5000 B-cells per uL of peripheral blood at any point during the…. Goal: People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. Phase/Status/Sponsor: Unknown phase; RECRUITING; VA Office of Research and Development.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human, multicenter, open-label Phase 1 trial testing CID-078, an oral Cyclin A/B-RxL inhibitor, for safety, tolerability, and early signs of anti-tumor activity in adults with advanced solid tumors. The study aims to identify a recommended dose for expansion and to compare safety and pharmacokinetics between the original and a new CID-078 formulation, including a test of the effect of food on its absorption. In the dose-expansion part, CID-078 will be studied for anti-tumor activity in three groups: triple-negative breast cancer, small cell lung cancer, and RB1-altered solid tumors, with a possible extra cohort expansion based on the data. Eligible participants include adults with progressed or refractory solid tumors and, in the expansion part, some adolescents aged 12 and older; key exclusions include prior CID-078 exposure, active brain metastases unless treated and stable, interstitial lung disease, significant QT prolongation risk, and certain viral infections or uncontrolled illnesses.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) is being studied. Conditions: Ductal Carcinoma in Situ • Eligibility: Inclusion Criteria: * Adults ≥ 18 years of age. * Patients with a core needle biopsy diagnosis consistent with ductal carcinoma in-situ (DCIS), Stage 0 breast cancer, who…. Goal: The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node biopsy (SLNB) procedure where the lymph nodes that drain the breast first are removed at the time of mastectomy. This recommendation for traditional SLNB is due to the risk of finding invasive cancer during surgical evaluation of the mastectomy specimen and the inability to accurately map the lymphatic channels once the breast is removed. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 is being studied. Conditions: Urothelial Carcinoma • Eligibility: Inclusion Criteria: Cohorts A and B * Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra * Participants…. Goal: This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is being studied. Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) • Eligibility: Inclusion Criteria: * Participant must have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic…. Goal: This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a new PET imaging tracer called 89Zr-labeled girentuximab (TLX250) that targets CAIX to visualize tumors. - It includes adults with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), or gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs), with separate baskets for these groups. - The study aims to learn how well this tracer images CAIX-expressing tumors and whether it could help guide precision medicine for these cancers. - Key exclusions include allergy to zirconium-89, recent cancer treatments or major surgery, uncontrolled brain metastases or severe heart disease, pregnancy, or life expectancy under 4 months. - The study is sponsored by Nantes University Hospital and is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells is being studied. Conditions: Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor • Eligibility: Inclusion Criteria: * Age \> 18 * Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery Exclusion Criteria: * Patients who cannot obtain an MRI…. Goal: The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma is being studied. Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma +3 • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Be willing to provide…. Goal: This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma is being studied. Conditions: Mantle Cell Lymphoma • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Confirmed pathology diagnosis of MCL with t(11;14)(q13;q32) translocation and/or cyclin D1 overexpression (e.g., positive immunohistochemistry staining). 3. MCL cells…. Goal: Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a French multicenter, retrospective, observational study that is currently recruiting to study rare primary liver cancers. It includes adults 18 and older with histologically confirmed hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma diagnosed after January 1, 2018. The study aims to describe clinical, histological and radiological features, collect tumor tissue and blood, and evaluate how treatments used in real-world care have performed to help determine the best sequencing of therapies. Key exclusions are lack of social security and no access to tumor tissue; living participants must consent to research for ancillary studies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer is being studied. Conditions: Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer +5 • Eligibility: Inclusion Criteria: * Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis * Estimated…. Goal: The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital, Ghent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care is being studied. Conditions: Congenital Uterine Anomaly • Eligibility: Inclusion Criteria: * females * age: 13 or older * encounters limited to: Yale New Haven Hospital, Bridgeport Hospital, Greenwich Hospital and Lawrence+ Memorial Hospital. * diagnosis of…. Goal: The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests an autism-adapted, therapist-guided internet-delivered exposure with response prevention (I-ERP) for OCD in children and adolescents with autism. It compares I-ERP to an active internet-delivered stress-management program (I-SM) to see which reduces OCD symptoms and whether the effects last over time. Participants are autistic children and teens aged 7–17 with OCD (CY-BOCS ≥16) and their caregivers, who will complete 12 online modules, with assessments at baseline, 12 weeks, and 3- and 6-month follow-ups; those in the I-SM arm may cross over to I-ERP after the primary endpoint. The study will evaluate clinical efficacy, durability, cost-effectiveness, and process implementation, with key exclusions including intellectual disability, certain severe comorbid conditions, current suicidality, recent CBT for OCD, ongoing OCD/anxiety treatment, or recent changes to OCD/ASD medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors is being studied. Conditions: Neuroendocrine Tumor of Pancreas (Disorder), Neuroendocrine Tumor Grade 1 • Eligibility: Inclusion Criteria: * Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI; * Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy…. Goal: Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Paoli-Calmettes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, randomized, open-label trial tests whether adding prophylactic cholecystectomy to primary tumor surgery for midgut neuroendocrine tumors reduces biliary stone disease two years after surgery. - It is for adults with midgut NETs (jejunum, ileum, or proximal colon) who need primary tumor resection, with or without gallstones at baseline. - Participants are randomly assigned to either primary tumor resection alone or primary tumor resection plus prophylactic cholecystectomy and followed for 104 weeks (2 years). - The main goal is to measure the cumulated incidence rate of biliary stone disease after surgery. - Key exclusions include prior bowel resection or prior cholecystectomy, existing biliary stone disease, tumors outside the specified gut locations, and certain liver or gallbladder conditions that could affect safety or eligibility.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a new PET imaging agent called 68Ga-HA-DOTATATE to identify tumors that have somatostatin receptors, using PET/CT or PET/MRI, and to check its safety. It is for people aged 14 and older who have known or suspected somatostatin receptor–positive tumors (like certain neuroendocrine tumors). The trial aims to show that the imaging is safe and to determine how accurately it detects tumors compared with standard CT scans. Key exclusions include pregnancy, allergy to DOTATATE, inability to lie still, claustrophobia, and weight limits for the scanner.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests a multimodal AI model to predict how bladder cancer patients will respond to neoadjuvant treatment, using MRI images, digital pathology, and clinical/genomic data. It is for bladder cancer patients who are planned for neoadjuvant therapy and radical cystectomy and who have histopathologic confirmation. This observational study will build and internally validate the AI model and assess how well it generalizes across centers. About 130 patients will be enrolled; exclusions include missing imaging or pathology data, prior local or systemic treatments, and poor-quality images.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) is being studied. Conditions: Neuroendocrine Tumors, Neuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1 +2 • Eligibility: Inclusion Criteria: * Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group); * Patients affected by…. Goal: This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Roma La Sapienza.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours is being studied. Conditions: Neuroendocrine Tumors • Eligibility: Inclusion Criteria: 1. Patient must be \> or equal to18 years of age and must have provided written informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET). Phase/Status/Sponsor: Unknown phase; RECRUITING; Peter MacCallum Cancer Centre, Australia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Age ≥ 18 yrs old. * Male or Female * Must have ECOG score ≤ 1. The body weight should be ≥40 kg. The life…. Goal: ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; OncoC4, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer is being studied. Conditions: Gastrectomy for Gastric Cancer, Gastrectomy, MLH1 Gene Mutation +1 • Eligibility: Inclusion Criteria: * Patients who underwent elective gastrectomy for Stage I-IV gastric cancer. * Surgery performed at the General Surgery Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS.…. Goal: DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have been developed and have demonstrated an association with mortality and, in some cases, with cancer incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) is being studied. Conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma • Eligibility: Inclusion Criteria: * Age greater than or equal to 18 years * Histologically confirmed treatment naive WM/LPL * Patients must have measurable disease as defined by at least…. Goal: The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Adult Solid Tumor, Adult Disease +5 • Eligibility: Inclusion Criteria: * Males and nonpregnant and non-breastfeeding females, aged ≥ 18 years of age at the time of signing the informed consent. * Subjects with advanced solid…. Goal: The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TOLREMO therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms is being studied. Conditions: Pancreatic Cyst • Eligibility: Inclusion Criteria: * Men and women aged \>18 years * Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection * Able to provide informed consent…. Goal: The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether a more complex exome analysis, which looks at structural DNA data like mutational signatures, tumor mutational load, large deletions, loss of heterozygosity, and gene amplifications, adds information beyond a standard exome test to guide cancer treatment. It is for adults (18+) with metastatic or locally advanced solid tumors who are starting first-line treatment and have tumor material available for testing. The study aims to find out how often the complex analysis would lead to a therapy choice that would not have been possible with the simpler exome analysis. Key exclusions include no tumor material available, inability to have a blood test, refusal of genetic analysis, pregnancy, HIV/HBV/HCV infection, or prior participation in EXOMA/EXOMA2.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics is being studied. Conditions: Breast Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Any participant over 18 years old who self-identifies as Black or African-American and signs an informed consent form, also referred to as the 'Permission to…. Goal: To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL is being studied. Conditions: Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult • Eligibility: Inclusion Criteria: 1. Male or female patients aged 18 years or older 2. Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABL positive and/ or FISH positive) acute lymphoblastic…. Goal: In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institute of Hematology & Blood Diseases Hospital, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma is being studied. Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Note: For research participants who do not speak English, a short form consent may…. Goal: This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a small, single-arm, open-label pilot trial testing an alternating low-dose schedule of 5-azacitidine and decitabine (5AZA-alt-DEC) for people with myelodysplastic syndromes (MDS) or MDS/MPN overlap disorders. It is for adults who may respond to hypomethylating agent therapy and have evidence of prior response to HMAs, and who meet safety and performance criteria. The study aims to learn how often patients have an overall response (complete, partial, or hematologic improvement), how long responses last, and the safety profile, with correlative lab studies to explore biology. Exclusions include very high-risk MDS by IPSS-R or prior azacitidine/decitabine therapy, pregnancy, uncontrolled illness, active HIV, and other factors that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) is being studied. Conditions: CLL • Eligibility: Inclusion Criteria: * Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment * Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 * Measurable disease…. Goal: The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BeOne Medicines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer is being studied. Conditions: Ovarian Neoplasms, Peritoneal Neoplasms • Eligibility: Inclusion Criteria: 1. Age: Women aged 19-85 years. 2. Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer. 3. Platinum Status: * Refractory: Disease progression during platinum-based chemotherapy.…. Goal: The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Seoul National University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AIO-BNHO CONNECT is a national, observational platform that collects and links patients’ clinical data with results from multi-gene NGS panels (more than 30 genes) for advanced solid tumors. It is for adults with locally advanced, inoperable, or metastatic tumors who have NGS data available; living patients must have provided informed consent, while data from deceased patients may be included. The aim is to learn how real-world genomic information relates to treatment outcomes and to map the current state of precision oncology in Germany across different care settings. There is also a decentralized tissue repository of annotated tumor samples to support future research. Exclusions include NSCLC, SCLC, and mesothelioma, and NGS results older than two years.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients. is being studied. Conditions: Lung Cancer • Eligibility: Inclusion Criteria: 1\. Age ≥ 60 years old; 2. A preliminary diagnosis of pulmonary结节 or lung tumor by chest CT; 3. Planning to undergo thoracoscopic lung resection surgery;…. Goal: This study, based on the Internet platform, involving family caregivers in preoperative management, not only promotes patient compliance with preoperative rehabilitation exercise, but also provides multi-way rehabilitation measures for elderly patients with limited mobility or medical difficulties, and also provides new ideas for other specialties。 Phase/Status/Sponsor: Unknown phase; RECRUITING; The Fourth Affiliated Hospital of Zhejiang University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma is being studied. Conditions: Extranodal Marginal Zone Lymphoma • Eligibility: Inclusion Criteria: 1. Men and women aged 18 years or older at the time of signing informed consent. 2. Able and willing to sign the informed consent form…. Goal: The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. Phase/Status/Sponsor: Unknown phase; RECRUITING; Izidore Lossos, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC is being studied. Conditions: SCLC, Extensive Stage • Eligibility: Inclusion Criteria: 1. Voluntary participation in clinical studies; fully understand, be informed about the study and have signed the informed consent form (ICF); willingness to follow and ability…. Goal: Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms is being studied. Conditions: Neuroendocrine (NE) Tumors, Endocrine Cancer • Eligibility: Inclusion Criteria: * Informed consent * Age ≥18 years * Histopathology confirmed endocrine neoplasm * Treatment with alkylating chemotherapy: Arm A; about to start alkylating chemotherapy, or Arm…. Goal: It has been showed that alkylating chemotherapy, particularly the widely used agent temozolomide, may cause high tumor mutational burden (TMB) in certain tumors by causing inactivating mutations in the DNA mismatch repair (MMR) system. This can cause therapy resistance and tumor progression but may also predict response for immunotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Uppsala University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Neoplasms • Eligibility: Inclusion Criteria: * Males or females aged 18 years or older (≥18 years). * Participants with pathologically confirmed advanced solid tumor (who have failed or are intolerant to…. Goal: The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount. Phase/Status/Sponsor: Unknown phase; RECRUITING; GlaxoSmithKline.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome is being studied. Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion: 1. Patients will have a diagnosis of CLL or SLL or RTand are: a) Cohort 1: Patients with treatment naïve CLL/SLL who meet IWCLL criteria for treatment…. Goal: This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II trial tests whether adding venetoclax to ASTX727 (decitabine plus cedazuridine) improves outcomes for bone marrow cancer in CMML and MDS/MPN with excess blasts compared with ASTX727 alone. - It is for adults with MDS/MPN overlap syndrome with at least 5% marrow blasts who meet certain health criteria. - Participants are randomly assigned to either ASTX727 plus venetoclax or ASTX727 alone, and the study looks at complete remission rates and other response and survival measures. - Key exclusions include pregnancy, uncontrolled central nervous system disease, significant cardiac disease, recent extensive prior MDS/MPN therapy, and other safety-related conditions (e.g., grapefruit product restrictions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer is being studied. Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features * Presence of metastatic disease that can be biopsied by…. Goal: This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an exploratory study to see how the PET/CT tracer 68Ga-FAPi-46 distributes in normal and cancer tissue and how much it accumulates, with tissue validation. It includes adults with a variety of cancers who are planned for surgical resection or biopsy, to compare imaging results with the actual tumor tissue. The study aims to define biodistribution, measure PET uptake, and relate it to FAP levels and to other tracers like 18F-FDG (and, if available, DOTATATE or FDOPA). Exclusions include pregnancy or nursing, starting new cancer therapy between scans, or conditions that could interfere with data; the trial is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia is being studied. Conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age between 12 and 55 * Eastern Cooperative Oncology Group (ECOG) ≤ 2 or…. Goal: This phase I/Ib trial tests the safety and side effects of asparaginase Erwinia chrysanthemi-recombinant-rywn (recombinant Erwinia asparaginase) and venetoclax in combination with blinatumomab and how well the combination works in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial is being studied. Conditions: NENS • Eligibility: Inclusion Criteria: 1. Provide written Informed Consent Form to voluntarily enroll in this study. 2. Men or women aged 18-75. 3. Histologically or cytologically confirmed metastatic neuroendocrine carcinoma,…. Goal: High-grade neuroendocrine neoplasms (NENs) comprise both well-differentiated grade 3 neuroendocrine tumors (G3 NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) nearly always include poorly differentiated NEC as the neuroendocrine component. Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital, School of Medicine, Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Scalable Communication Modalities for Returning Genetic Research Results is being studied. Conditions: Hereditary Breast and Ovarian Cancer, Lynch Syndrome • Eligibility: Inclusion Criteria: -Women in the BWHS previously included in the targeted breast cancer sequencing project Exclusion Criteria: * Women with known cognitive impairments * Women with variant of…. Goal: Efforts to examine the utility of alternate modalities for genetic results disclosure has widespread implications for how precision medicine research might yield direct health benefits for study participants. This study will examine the efficacy of an online self-guided program to return genetic results to a racial minority cohort population. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Boston University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Copanlisib Plus Venetoclax in R/R DLBCL is being studied. Conditions: Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma • Eligibility: Inclusion Criteria: * A confirmed diagnosis of DLBCL according to the 2016 WHO classification. Patients with high-grade B-cell lymphoma with translocations of MYC and BCL-2 and/or BCL-6 are…. Goal: This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study are: * Copanlisib * Venetoclax Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase I trial tests whether giving stereotactic body radiation therapy (SBRT) followed by the radiopharmaceutical Lutetium-177 DOTATATE (177Lu-DOTATATE PRRT) is safe and may be effective for large, unresectable, well-differentiated digestive-system neuroendocrine tumors that express somatostatin receptors. It is for adults with grade 1-2 tumors that cannot be removed surgically and have progressed after one or two prior systemic therapies. The study aims to determine the acute toxicity of PRRT after SBRT compared with historical controls, and also to measure tumor response at 3 months, progression-free survival, and patient-reported toxicity. Exclusions include prior radiation to the same site (including prior PRRT), brain metastases or metastases extending into the spinal canal, and inability to secure insurance coverage for the planned radiation treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether germline genetic testing with the investigational MyeloGen Gene Panel is feasible for people with myeloid cancers. - It is for adults 18 and older who have a histologically confirmed myeloid malignancy or bone marrow failure within the last 6 months. - Researchers want to learn how to best incorporate routine germline testing into clinical care for people with blood cancers. - Exclusion criteria include not being able to safely have a skin biopsy and having previously undergone germline testing for predisposition to myeloid malignancies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations is being studied. Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation +11 • Eligibility: Inclusion Criteria: 1. Women must be ≥ 30 and ≤ 50 years of age. 2. Premenopausal women with a documented deleterious mutation in one of the following ovarian…. Goal: This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an electrocardiogram (ECG)…. Goal: This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Canadian Lung Outcomes in Users of Vaping Devices Study is being studied. Conditions: Small Airways Diseases, Vaping, Vaping Related Disorder +2 • Eligibility: Inclusion Criteria: Adolescent arm: * Aged ≥12 and \<19 years old * Either 1) use neither combustible cigarettes nor e-cigarettes or 2) use e-cigarettes exclusively Adult arm: *…. Goal: Vaping is increasingly popular with both adolescent and adult Canadians, but the long-term health impacts remain unknown. We believe that the tools we currently have to detect lung disease in people who vape may be insufficient and propose new ways to find lung injuries that may impact them over the course of their lives. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of British Columbia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests a radioactive drug called 212Pb-VMT-α-NET to find a safe dose for future studies in people with neuroendocrine tumors. It is for adults with well-differentiated neuroendocrine tumors that cannot be cured with surgery and have progressed, including those who have had prior PRRT and have tumors that light up on SSTR PET scans. The study aims to learn whether the treatment is safe and tolerable, estimate the kidney radiation dose using imaging, and determine the recommended dose for future trials. The trial uses two treatments about 8-10 weeks apart, with kidney-protective amino acids and anti-nausea meds, and participants are followed for at least 6 months (with lifelong follow-up); key exclusions include pregnancy or breastfeeding, poor kidney or liver function, very low blood counts, recent cancer therapy, or a history of congestive heart failure.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a patient’s own T cells that are genetically engineered to target mesothelin, given directly into the pleural space to treat malignant pleural disease. - It includes adults with MPD from mesothelioma, metastatic non-small cell lung cancer to the pleura, or breast cancer to the pleura who have already had at least one prior treatment and show mesothelin expression or elevated SMRP. - The study aims to find a safe dose and learn how these CAR T cells affect the cancer and the patient, with an initial dose‑escalation Phase I and a Phase II part that adds pembrolizumab for mesothelioma. - Key exclusions include active CNS metastases, certain autoimmune or cardiac conditions, active infections, pregnancy, and other health issues that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer is being studied. Conditions: Localized Prostate Cancer • Eligibility: Inclusion Criteria: * Language spoken: Finnish, English or Swedish * Mental status: Patients must be able to understand the meaning of the study * Informed consent: The patient…. Goal: Magnetic resonance imaging (MRI) has improved detection of clinically significant prostate cancer (PCa). MRI-guided transurethral ultrasound ablation (MRI-TULSA) system incorporates precise diagnosis and simultaneous ablation of prostate tissue enabling lesion-targeted treatment of PCa. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS is being studied. Conditions: Polycystic Ovary Syndrome, Metformin • Eligibility: Inclusion Criteria: * • Newly diagnosed women of reproductive age (18 - 35 years) PCOS patients Exclusion Criteria: * • Patients having known similar endocrine disorders (hypothyroidism, hyperprolactinemia,…. Goal: The aim of this study is to see the associations of metabolic responses of metformin with single nucleotide polymorphisms (SNPs) (rs628031 and rs2282143) of solute carrier family 22 member 1 (SLC22A1) gene in women with polycystic ovary syndrome (PCOS). This prospective clinical study will be conducted in the department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU) from February 2023 to September 2024 over a period of two years. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have NRAS mutation in…. Goal: This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation. Binimetinib blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth when an NRAS mutation is present. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an AKT mutation…. Goal: This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have a PIK3CA mutation…. Goal: This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma +2 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol * Patients must fulfill all…. Goal: This phase II MATCH treatment trial tests how well larotrectinib (LOXO-101) works in treating patients with cancer that has certain genetic changes. Larotrectinib (LOXO-101) is used in patients whose cancer has a mutated (changed) form of a gene called NTRK. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patient's tumor must have activating HER2…. Goal: This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations. Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria: * Pathologically confirmed diagnosis of high-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma * Presence of measurable recurrence, with RECIST measurable disease at the time…. Goal: The purpose of this phase I study is to test the safety of different dose levels of specially prepared cells collected called "modified T cells". In the screening part of this study the tumor was found to have a protein called MUC16. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human study to test [203Pb]VMT-α-NET as an imaging agent to identify neuroendocrine tumors with SPECT/CT, with the aim of guiding future alpha-radiation therapy using [212Pb]VMT-α-NET. It is for adults with well-differentiated neuroendocrine tumors of the foregut or midgut that express somatostatin receptors and have at least one measurable tumor site. The study will give a very small dose of the imaging agent and perform serial imaging over four days, along with blood tests, to see if the tumors can be identified. If imaging can locate the tumors, the trial hopes to pave the way for a targeted alpha-radiation therapy for treatment-resistant disease. Exclusions include pregnancy or breastfeeding, a requirement to use contraception if pregnancy is possible, and other health or treatment conditions that could affect safety or imaging.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms is being studied. Conditions: Breast Cancer • Eligibility: * Select 600 Breast Cancer LCIS Patients who are suitable for breast tissue biopsy * High risk of breast cancer is defined as at least one breast biopsy…. Goal: Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The EPigenetic Consequences in Children of Intravenous vs Volatile Anaesthesia for Surgery (EPIVA) is being studied. Conditions: Hypospadias, Anesthesia; Adverse Effect, Perioperative Complication +1 • Eligibility: Inclusion Criteria: * Age ≥6 months and ≤ 3 years at time of initial operation * Undergoing hypospadias surgery * Maintenance phase of anaesthesia for procedure has an…. Goal: More than half a million children have an anaesthetic each year in the UK. Though anaesthesia is usually thought to be safe and necessary to improve health, concerns remain the effects that the drugs used may have on brain development in children and the potential long-term consequences for health. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Hospital Southampton NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests a radiopharmaceutical called 177Lu-CTR-FAPI for treating advanced metastatic gastrointestinal cancers that express fibroblast activation protein (FAP). It is for adults 18 to 75 with high FAP expression confirmed by 68Ga-FAPI PET/CT and at least one measurable tumor, and a good overall condition (ECOG 0-1). Researchers will assess safety, radiation dosimetry, and early signs of treatment activity. The study is single-centre, single-arm, non-blinded, plans to enroll about 20 patients, and is not yet recruiting; key exclusions include uncontrolled cancer-related conditions, significant organ or heart dysfunction, active infections (HBV/HCV/HIV), pregnancy, and inability to use contraception.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma is being studied. Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor +5 • Eligibility: Inclusion Criteria: All Patients * Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or…. Goal: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cellectar Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Key Inclusion Criteria: * Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) * Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment * Measurable disease by imaging…. Goal: To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BeiGene.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genetic Testing in African Americans is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Peritoneal Cancer • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years of age. 2. New diagnosis of ovarian, endometrial, fallopian, or primary peritoneal carcinoma. 3. Diagnostic procedure performed at AU Health Medical…. Goal: This is a pilot/feasibility study to conduct genetic testing using tumor/blood samples of African American and Caucasian patients with ovarian and endometrial cancer following surgery at AU Health Medical Center. The aim of the pilot/feasibility study is to sequence a panel of cancer genes on paired tumor/blood (germline) samples of patients with ovarian and endometrial tumors at a two-week time point following surgery at AU Medical Center. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Augusta University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) is being studied. Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer +5 • Eligibility: Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status…. Goal: This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests CAM2029, a subcutaneous octreotide depot, against the standard long-acting medicines octreotide LAR or lanreotide ATG in people with advanced, well-differentiated GEP-NET. It aims to learn which treatment provides better disease control and safety for this group. Eligible participants are adults 18 or older with unresectable or metastatic, well-differentiated GEP-NET that is somatostatin receptor–positive and with ECOG 0–2. Exclusion criteria include progression on SSA therapy, brain metastases, more than 6 months of prior long-acting SSA, refractory carcinoid symptoms, and prior extensive targeted therapy, chemotherapy, embolization, or radioligand therapy. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes is being studied. Conditions: Ovarian Cancer, Prostate Cancer, Pancreas Cancer • Eligibility: Inclusion Criteria: * MSK patient age 18 years or older. * Diagnosed with or presumed by physician to have prostate cancer, or pancreatic cancer and recommended to undergo,…. Goal: This study will evaluate patients' experiences with having gynecologic or prostate medical oncologists and surgeons offer them genetic testing, and having genetic counselors return the test results to patients over the telephone. This is different from the usual approach to genetic testing, where gynecologic or prostate medical oncologists and surgeons refer their patients to a genetic counselor in order to have these tests done, and the genetic counselors return the test results to the patient in person or over the telephone. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE is being studied. Conditions: Neuroendocrine Tumors • Eligibility: Inclusion Criteria: * Patients aged ≥ 18 years. * Histologically confirmed diagnosis of unresectable, well-differentiated GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs). measurable site of disease per RECIST v1.1 (Response evaluation…. Goal: The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; ITM Solucin GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase II, open-label, single-arm study testing AK104 (Cadonilimab) as a monotherapy for adults with recurrent or metastatic high-grade neuroendocrine carcinoma of the cervix who have already received prior treatment. It aims to estimate progression-free survival at 6 months and to assess response rates, duration of response, safety, and tolerability. The study also looks at whether HPV cell-free DNA in the blood could serve as a marker of response. Key exclusions include brain metastases, active infections, HIV or hepatitis B/C infection, autoimmune disease, and recent or prior immunotherapy or other anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent form; 2. Body weight 60 to 90 kg. 3. Histologically confirmed melanoma with the…. Goal: The aim of the study BCD-263-1 is to prove the comparability of the pharmacokinetics and similarity of the safety, immunogenicity and pharmacodynamic profiles of BCD-263 and Opdivo following intravenous administration to subjects with advanced unresectable or metastatic melanoma of the skin. The study will have randomized, double-blind design with parallel assignment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Biocad.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DOTATOC PET/CT for Imaging NET Patients is being studied. Conditions: Neuroendocrine Tumors, Insulinoma, Gastrinoma +13 • Eligibility: Inclusion Criteria: All subjects: * World health organization performance status 0-2 * Able to provide written informed consent/assent (or consent by guardian for subjects \<19 years) * Patients…. Goal: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; British Columbia Cancer Agency.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma is being studied. Conditions: Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II +3 • Eligibility: Inclusion Criteria: 1. Histologically confirmed Merkel cell carcinoma (MCC) which is either: * clinical stage I; * pathological stage I with positive LVSI only; * clinical or pathological…. Goal: The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Melanoma and Skin Cancer Trials Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a GIMEMA platform to collect patient-reported outcomes about quality of life and symptom burden in Italian patients with Philadelphia chromosome negative myeloproliferative neoplasms. - It aims to learn how the disease and its treatments affect wellbeing, symptoms, and daily functioning. - It includes adults in Italy with PV, ET, or PMF (including pre-PMF, overt-PMF, and MF after ET or PV) diagnosed within the past year, who have completed a baseline PRO assessment. - Participants must be able to read Italian and have no major psychiatric or cognitive disorders that would hinder self-reporting. - The trial is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is being studied. Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma +3 • Eligibility: Inclusion Criteria: * Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug. * Male subject…. Goal: The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study is testing the creation and use of three-dimensional cell models called assemblyloids from people with atypical PSC to study how ciliopathy-related gene variants affect the disease. - It is for adults aged 18 to 90 of any sex who have confirmed atypical PSC or are suspected PSC, including those previously genotyped for ciliopathy-related variants. - Researchers aim to learn how loss of cilia in cholangiocytes may contribute to inflammation, fibrosis, and progression of PSC, and to use these models to test potential drugs targeting these genetic mutations. - The trial is currently active but not recruiting, and people with chronic viral hepatitis (HCV RNA positive or HBsAg positive) are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies is being studied. Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL) +9 • Eligibility: Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures * Histologically or cytologically confirmed diagnosis…. Goal: This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax. Phase/Status/Sponsor: Unknown phase; COMPLETED; Prelude Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors is being studied. Conditions: Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor • Eligibility: Inclusion Criteria: * Have a Karnofsky performance status \>= 70 or Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (i.e. the patient must be able to care…. Goal: This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Roswell Park Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer +2 • Eligibility: Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Diagnosed with non-small cell lung cancer (NSCLC) OR melanoma AND initiating therapy with single…. Goal: This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy is being studied. Conditions: Colorectal Cancer, Precancerous Condition • Eligibility: DISEASE CHARACTERISTICS: * Scheduled to undergo colonoscopy at the Vanderbilt University Medical Center or the Tennessee Valley Veterans Administration Medical Center * No prior genetic colorectal cancer syndromes…. Goal: RATIONALE: Collecting and storing samples of tissue, blood, and other body fluids to test in the laboratory and gathering information about health and lifestyle from participants may help doctors learn more about cancer risk factors. PURPOSE: This clinical trial is looking at biological, genetic, and lifestyle risk factors for developing colorectal adenomas or polyps in participants undergoing colonoscopy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vanderbilt University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 is being studied. Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Agreement to provide fresh or archived tumor tissue sample within 3 years * Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced…. Goal: This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib). Phase/Status/Sponsor: Unknown phase; COMPLETED; Risen (Suzhou) Pharma Tech Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) is being studied. Conditions: PDAC - Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy * Patients able to undergo at least two…. Goal: The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). Phase/Status/Sponsor: Unknown phase; SUSPENDED; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Using Visual Arrays to Support Understanding of Genetic Risk is being studied. Conditions: Decision Aid • Eligibility: Inclusion Criteria: * ability to read and understand English * opt-in consent Exclusion Criteria: * incorrect responses to validation questions. Goal: The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stephanie B. Seminara, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma is being studied. Conditions: Solid Tumor, Lymphoma • Eligibility: Inclusion Criteria: 1. Histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid malignant tumor (including lymphoma; dose-escalation phase only) that has failed to respond to standard therapies;…. Goal: The primary goal of this Phase 1 study is to characterize the safety and tolerability of DZ-002 and establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of DZ-002 administered on a weekly schedule in patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of DZ-002 will also be assessed. Phase/Status/Sponsor: Unknown phase; COMPLETED; Da Zen Theranostics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.